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Abstract
Background: eHealth interventions are widely used in clinical trials and increasingly in care settings as well; however, their
efficacy in real-world contexts remains unknown. ReMindCare is a smartphone app that has been systematically implemented
in a first episode of psychosis program (FEPP) for patients with early psychosis since 2018.
Objective: The objective of this study was to assess the efficacy of ReMindCare after 19 months of use in the clinic and varying
use by individual patients.
Methods: The integration of the ReMindCare app into the FEPP started in October 2018. Patients with early psychosis self-selected
to the app (ReMindCare group) or treatment as usual (TAU group). The outcome variables considered were adherence to the
intervention and number of relapses, hospital admissions, and visits to urgent care units. Data from 90 patients with early psychosis
were analyzed: 59 in the ReMindCare group and 31 in the TAU group. The mean age of the sample was 32.8 (SD 9.4) years,
73% (66/90) were males, 91% (83/90) were White, and 81% (74/90) were single.
Results: Significant differences between the ReMindCare and TAU groups were found in the number of relapses, hospitalizations,
and visits to urgent care units, with each showing benefits for the app. Only 20% (12/59) of patients from the ReMindCare group
had a relapse, while 58% (18/31) of the TAU patients had one or more relapses (χ2=13.7, P=.001). Moreover, ReMindCare
patients had fewer visits to urgent care units (χ2=7.4, P=.006) and fewer hospitalizations than TAU patients (χ2=4.6, P=.03). The
mean of days using the app was 352.2 (SD 191.2; min/max: 18-594), and the mean of engagement was 84.5 (SD 16.04).
Conclusions: To our knowledge, this is the first eHealth intervention that has preliminarily proven its benefits in the real-world
treatment of patients with early psychosis.
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High interest in eHealth services and now digital and mobile
health has been noted in many recent studies among patients
with psychotic disorder diagnoses [1,2]. With COVID-19, this
interest in digital health has surged, and the need to expand
access to care through smartphones has become patent.
Smartphone apps have been proposed as tools to mitigate social
isolation, lack of access to care, and other triggers caused by
the pandemic [3-5]. Researchers have already demonstrated that
access to and use of technology among people with psychosis
is nearly equivalent to that in the general population [6-8], but
less is known about the actual efficacy of apps in care.
Apps have already seen growth in care for patients with early
course psychosis. Many studies are using real-time ecological
momentary assessment (EMA) surveys to monitor symptoms
and experiences and identify early indicators of relapse [9].
Beyond relapse prediction, these EMA data can offer novel
information on the longitudinal health status of patients, which
could improve treatment and shared decision making between
patient and physician [10]. Finally, eHealth services may be a
major resource to enhance the benefits of the first episode of
psychosis programs (FEPPs) for early psychosis, which can
foster recovery [11] and reduce the risk of hospitalization and
relapse [12,13].
Specific apps targeting schizophrenia have already been created
and offer promising results. Examples of these innovative
interventions are the Actissist [14] and the ExPRESS [15]
interventions, which demonstrated potential in improving the
quality of treatment of patients with early psychosis. Another
example is the CrossCheck app [16], which demonstrated
potential for identifying and dismantling dysfunctional beliefs
that contribute to maintenance and distress associated with
psychotic symptoms. Despite the widespread use of these
eHealth interventions and high rates of efficacy reported in
clinical trials, the efficiency and actual efficacy of these
interventions in real-world clinical practice remains unknown
[17].
One reason for the lack of initial success of health apps in
clinical settings is lack of engagement. Often engagement in
academic studies does not translate into real-world use [18,19].
Indeed, some studies found a negative correlation between the
time spent using eHealth apps and the engagement of patients
[20,21]. In addition, many clinicians expressed their concern
that if these systems integrate seamlessly with clinical workflow,
they will result in an increase in the clinicians’workload [22,23],
which might affect their engagement with the app.
Other concerns have also limited efforts to integrate these apps
into care settings. In our previous study [8], we found that 20%
to 23% of patients felt anxious, suspicious, or paranoid
concerning the internet, and almost 25% of patients perceived
that use of the internet was directly related to one of their
relapses. In addition, some studies indicated that excessive
eHealth communications could be regarded as intrusive or
irritating [24,25] or could increase worries about illness [25].
These potential harms of eHealth interventions must also be
taken into consideration.
Considering these factors, it is clear that eHealth interventions
shown to be feasible must now be assessed for effectiveness,
efficacy, and efficiency [26] in real-world settings. With this
objective in mind and to improve the daily treatment of patients
with psychosis, we designed the ReMindCare app. The protocol
followed for the design process and implementation of the app
is published elsewhere [27]. In this protocol, we introduced
ReMindCare as a smartphone app plus a clinician dashboard,
developed to be implemented in a FEPP for patients with early
psychosis.
To the best of our knowledge, ReMindCare is the first eHealth
intervention for patients with early psychosis that has been
systematically integrated into daily clinical practice, finally
filling the gap between research and clinical practice [2,17].
The aim of this study was to assess the efficacy and clinical
outcomes of the use of the app after 19 months in terms of
adherence to ReMindCare, relapse prevention, hospital
admissions, and visits to urgent care units compared with
treatment as usual (TAU) without the app.
Methods
Study Setting
The app was systematically integrated into the daily clinical
workflow in a FEPP at the University Clinic Hospital of
Valencia, Spain. This FEPP started in 2010 with the objective
of improving early detection, evaluation, and personalization
of treatment. It covers a total of 330,000 inhabitants included
in Area 5 of Valencia city. The incidence of novel psychotic
disorders in this area has gradually increased during the 10 years
since the program started. Currently, the FEPP in the clinic
hospital has a mean of 30 to 35 new patients with psychosis per
year.
The implementation of the ReMindCare app into the FEPP and
into clinical practice started in October 2018 and is still in use
today. In this study, we present the results from the first 19
months of use of the app.
Neither patients nor physicians received any remuneration or
compensation for participating in the program or using the app.
The use of the app was offered as an extra free service to the
patients in the program.
Participants
Recruitment and Enrollment
The patient’s psychiatrist of reference offered the use of the
ReMindCare app to every outpatient from the FEPP who met
the criteria for inclusion. Once patients enrolled in the study,
they were encouraged to use the app as long as they remained
in the program (maximum period of 5 years). To use the app,
all patients signed an informed consent form and completed
baseline assessments.
Eligibility Criteria
To be considered for this intervention, patients met the following
criteria: (1) diagnosis of psychotic disorder following DSM-5
(Diagnostic and Statistical Manual of Mental Disorders, 5th
Edition) criteria, interview conducted by a licensed clinician,
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(2) aged between 17 and 65 years, (3) smartphone ownership
with an internet connection that allows for the proper installation
and functioning of the app, and (4) less than 5 years of illness
duration. However, it must be stated that some patients remained
in the program for more than 5 years. These patients remained
in the FEPP to prevent potential relapses, as they experienced
severe fluctuations in their symptoms.
Criteria for exclusion were (1) lack of ability to use and master
a mobile device and the internet, (2) refusal to sign an informed
consent form, and (3) level of Spanish or English not fluent




ReMindCare is a free and user-friendly app that conducts daily
evaluations of the health status of patients with early psychosis
by offering quick questionnaires (Figure 1).
Two types of questionnaires were included:
• Daily questionnaires: 3 daily questions assessing levels of
anxiety, sadness, and irritability (Figure 2)
• Weekly questionnaires: 18 weekly questions aimed at
assessing adherence to medication (1), the presence of side
effects from antipsychotic medication intake (5), the attitude
toward medication intake (3), and the presence of prodromal
psychosis symptoms (9)
Figure 1. Screenshot of the ReMindCare app home screen.
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Figure 2. Screenshot of the ReMindCare daily questionnaire.
In addition, the app offered preset alerts in case of low
engagement or abrupt changes in survey responses. Low
engagement alerts were set off if patients did not respond to the
surveys for 7 days or more, while abrupt changes were
considered when there was a difference of 2 points (Likert scale
1 to 5) or more between each question in the last 2 surveys
answered. These alerts notified physicians by email and were
also displayed in the profile of the patient on the app’s website
portal.
All data captured by the app were accessible for physicians on
a password-protected dashboard. Moreover, physicians could
download a summary pdf of these data from the dashboard and
attach it to the electronic clinical record of the patient in the
hospital database.
The app is available in 3 languages (Spanish, English, and
Catalán), although we are open to developing new language
versions of the app. Our aim is to extend the use of the app to
other countries, and adaptation of the app to different languages
would be necessary to ensure patient engagement. Further
information about the design process of the app and its
characteristics can be found in the ReMindCare app study
protocol [27].
Patients who used the app (ReMindCare group) did not
experience any changes in their usual clinical appointments.
Treatment as Usual
The TAU group comprised patients who met the criteria but
rejected using the app. In this group of patients, 42% (13/31)
were patients with low adherence to treatment, 26% (8/31) did
not perceive any benefit from using the app, and 26% (8/31)
were suspicious about technology and their privacy.
Additionally, 6% (2/31) were included in this group because
they only used the app for 2 days. These patients continued with
their usual psychiatric treatment at the FEPP and were not
adversely affected by their rejection of participation.
Procedure
Once patients enrolled in the FEPP, after an interview with their
psychiatrist of reference, they were asked to complete some
baseline assessments. Subsequently, they were offered the use
of the ReMindCare app. The ReMindCare app was described
as an extra tool developed by the FEPP that could help them
manage their symptoms and help clinicians better understand
their illness evolution. The main characteristics of the app were
listed. After receiving this information, patients decided whether
they were willing to use the app. If they were not interested,
they were placed in the TAU group. If patients were interested,
they were informed in more detail by an expert clinician about
the installation process, characteristics of the app, and ethics
and data privacy information.
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Patients could use the ReMindCare app to contact their
psychiatrist of reference directly in case of symptoms worsening
by using the urgent consultation request tab on the home screen
of the app. If they clicked the urgent consultation request, their
clinician would contact them by phone within 48 hours (patients
who did not use the app could call the department of psychiatry
at the hospital and be referred to their psychiatrist or attend an
urgent care unit). In addition, clinicians contacted patients by
phone in response to preset alarms. As a result of these phone
calls and the information that patients provided to the clinician,
urgent care visits could be scheduled if necessary. With these
services, we aimed to improve the detection of early psychotic
symptoms and reduce the visits to urgent care units at the
hospital, as these prodromal symptoms will be primarily treated
by a phone call or in the outpatient services. If patients did not
make an urgent consultation request and no preset alarms were
set off, they continued with their scheduled clinical
appointments.
Furthermore, the use of the ReMindCare app changed the
dynamics of the clinical appointment at the outpatient services.
Once patients arrived at the clinical appointment, physicians
accessed their profile on the ReMindCare’s physician dashboard
and used the information provided for patients to guide them
through the interview. Clinicians used shared decision making
with patients and discussed their responses.
Data Collection and Measures
Baseline
After patients were enrolled in the FEPP, the following data
were collected:
• Sociodemographic information: age, gender, country,
ethnicity, marital status, education level, employment status,
and cohabitation
• Clinical information: antipsychotic medication, injectable
medication, length of illness, associated illnesses, suicidal
attempts, Clinical Global Impression Severity of Illness
scale (CGI-SI) [28], Global Assessment of Functioning
(GAF) [29], Positive and Negative Syndrome Scale
(PANSS) [30], Premorbid Adjustment Scale (PAS) [31],
date discharged from FEPP
Outcome Measures
• Efficacy: number of relapses, number of visits to the
hospital urgent care units, and number of hospital
admissions in the ReMindCare group compared with the
TAU group
• Feasibility: number of patients who agreed to use the app
compared with the patients who did not use it (TAU)
• Compliance and engagement: number of times patients
answered the questionnaires when presented and number
of months using the app, patients dropouts, plus number of
urgent consultation requests
Data Analysis
Data were analyzed with the statistical program SPSS Statistics
version 22 (IBM Corp). The cohort was divided into two groups:
ReMindCare group patients agreed to use the app and used it
for at least 1 month; the TAU group patients did not use the app
or used it for less than 1 month. To consider that patients in the
ReMindCare group had a relapse while using the app, patients
had to be actively using the app. Relapses of patients who did
not use the app for more than 2 months were not considered as
relapses while using the app. Descriptive statistics (mean,
standard deviation, frequency, and percentage) were determined,
and chi-square test analysis was performed to compare the
differences between the ReMindCare group and the TAU group.
Ethics, Data Privacy, and Participant Safety
The ReMindCare app project received approval from the
research ethics committee of the faculty of medicine at the
University of Valencia and from the research ethics committee
of the Sanitary Research Institute of the University Clinic
Hospital of Valencia, Spain.
To protect the data sent by patients, communications to the
platform were encrypted with a transport layer security
certificate from the Generalitat Valenciana and were sent
through the https protocol. The hospital infrastructure is
protected through a reverse proxy, which enhances security by
establishing a single access point to it and hiding all inner
infrastructures. Moreover, the integration of the app into the
hospital systems was subjected to Organic Law 3/2018:
protection of personal data and digital rights guarantee,
December 5th, the Spanish organic law adaptation of the General
Data Protection Regulation.
Results
Data from 90 patients were analyzed: 59 used or are using the
app (ReMindCare group) and 31 did not agree to use the app
(TAU group). Characteristics of both groups are displayed in
Tables 1 and 2.
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Table 1. Sociodemographic data.
χ2 (P value)TAUbRCa groupTotalCharacteristic
1.5 (.57)34.3 (1.7)32.1 (1.2)32.8 (9.4)Age in years, mean (SD)
—c7 (23)12 (20)19 (21)24 and younger, n (%)
—18 (58)40 (68)58 (64)25-44, n (%)
—6 (19)7 (12)13 (14)45 and older, n (%)
1.7 (.19)25 (81)40 (68)66 (73)Gender (male), n (%)
4.2 (.04)30 (97)48 (81)79 (87)Native country (Spain), n (%)
4.6 (.33)31 (100)51 (86)83 (91)Race (White), n (%)
5.2 (.16)———Marital status, n (%)
—23 (74)50 (85)74 (81)Single
—6 (19)5 (9)11 (12)Married
—2 (7)4 (7)85 (7)Other
5.9 (.05)———Educational level, n (%)
—2 (7)0 (0)2 (2)Primary
—18 (58)27 (46)45 (50)Secondary
—11 (36)32 (54)43 (48)College or higher
5.6 (.24)———Employment status, n (%)
—13 (42)16 (27)29 (32)Employed
—4 (13)16 (27)21 (23)Student
—13 (42)25 (42)38 (42)Not employed
—1 (3)2 (3)3 (3)Unable to work
2.3 (.51)———Cohabitation, n (%)
—3 (10)3 (5)6 (7)Alone
—20 (65)39 (66)60 (66)Family_birth
—5 (16)6 (10)11 (12)Family_own
—3 (10)11 (19)14 (15)Other
aRC: ReMindCare.
bTAU: treatment as usual.
cnot applicable.
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Table 2. Baseline clinical information.
χ2 (P value)TAUbRCa groupTotalCharacteristics
4.4 (.03)10 (32)8 (14)18 (20)Injectable medication, n (%)
12.3 (.002)5.7 (0.5)3.9 (0.4)10.5 (2.8)Length of illness in years, mean (SD)
—c0 (0)13 (22)13 (14)0-1, n (%)
—13 (42)30 (51)43 (48)2-5, n (%)
—18 (58)16 (27)34 (38)More than 6, n (%)
0.2 (.63)11 (36)18 (31)29 (32)Associated illnesses, n (%)
2.1 (.15)3 (10)12 (22)16 (18)Suicidal attempts, n (%)
2.7 (.26)4.4 (0.1)4.1 (0.1)4.2 (0.9)CGI-SId, mean (SD)
—3 (11)10 (19)13 (16)Mild (1-3), n (%)
—24 (86)42 (81)66 (83)Moderate (4-5), n (%)
—1 (4)0 (0)1 (1)Severe (>5), n (%)
1.3 (.52)59.8 (1.7)61.3 (1.7)60.7 (10.9)GAFe, mean (SD)
—4 (14)4 (8)8 (10)Mild (71-100), n (%)
—16 (57)35 (69)51 (65)Moderate (51-70), n (%)
—8 (29)12 (24)20 (25)Severe (<50), n (%)
52.1 (.28)68.7 (4.6)64.5 (2.2)65.9 (18.8)PANSSf, mean (SD)
23.9 (.58)18.7 (6.8)18.7 (5.8)18.4 (6.5)Positive
28.2 (.17)17.9 (9.3)15.4 (5.1)18.9 (6.9)Negative
12.8 (.03)2.8 (1.5)2.0 (0.2)2.3 (1.3)N5. Difficulty in abstract thinking
12.9 (.02)1.9 (1.7)1.6 (1.1)1.7 (1.3)N6. Lack of spontaneity and flow conversation
32.2 (.41)70.5 (22.2)66.1 (14.7)32.3 (8.2)General
9.9 (.01)1.3 (0.7)1.1 (0.4)1.1 (0.7)G5. Mannerism and posturing
9.1 (.70)10.14 (0.6)10.7 (0.5)10.5 (2.8)PASg, mean (SD)
4.3 (.12)———Relapses_Baseline, n (%)
—15 (48)38 (64)53 (59)0
—7 (23)14 (24)21 (23)1
—9 (29)7 (12)16 (18)≥2
0.9 (.61)———UCUh visits_Baseline, n (%)
—7 (23)19 (32)26 (29)0
—13 (42)23 (39)36 (40)1
—11 (36)17 (29)28 (31)≥2
4.6 (.10)———Hospitalizations_Baseline, n (%)
—3 (10)16 (27)19 (21)0
—18 (58)32 (54)50 (56)1
—10 (32)11 (19)21 (23)≥2
aRC: ReMindCare.
bTAU: treatment as usual.
cnot applicable.
dCGI-SI: Clinical Global Impression Severity of Illness scale
eGAF: Global Assessment of Functioning.
fPANSS: Positive and Negative Syndrome Scale.
gPAS: Premorbid Adjustment Scale.
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hUCU: urgent care units.
Sociodemographic Analysis
The mean age of the sample was 32.8 (SD 9.4) years, 73%
(66/90) were males, 91% (83/90) were White, and 81% (74/90)
were single. No significant differences were found between the
ReMindCare and TAU groups in any of the sociodemographic
information analyzed except for the native country. We found
that nearly every immigrant considered for inclusion agreed to
use the app (ReMindCare group 19% [10/11], TAU group 3%
[1/11]; χ2=4.2, P=.04). Further information regarding
sociodemographic analysis of the data is displayed in Table 1.
Baseline Clinical Analysis
Significant differences were found between the ReMindCare
group and TAU group in some clinical factors. With regard to
injectable medication, 32% (10/31) of TAU patients were taking
injectable medication, while only 14% (8/59) of the ReMindCare
took it (χ2=4.4, P=.04). Every new patient in the FEPP (length
of illness: 0-1 year) agreed to use the app (13/90, 22%), and
58% (18/31) of the TAU group had their illness for 6 or more
years (χ2=12.3, P=.002). Moreover, the TAU patients showed
higher scores on the PANSS N5 and N6 negative subscales and
G5 in the general subscales (χ2=12.8, P=.03; χ2=12.9, P=.02;
χ2=9.9, P=.01, respectively).
Considering medication, 20% (18/90) of patients were taking
injectable medications, 32% (29/90) of the patients suffered
from another illness, and 18% (17/90) had a prior suicidal
attempt. The mean of the CGI-SI was 4.2 (SD 0.9), the GAF
mean=60.7 (SD 10.9), PANSS mean 65.9 (SD 18.8), and PAS
mean 10.5 (SD 2.8). Finally, 12% (11/90) of patients were
discharged from the FEPP. No significant differences were
found between the groups in any of these factors. Moreover, no
significant differences were found between the ReMindCare
group and TAU group in terms of the number of relapses
(χ2=4.3, P=.12), visits to urgent care units (χ2=0.9, P=.61), or
the number of hospitalizations (χ2=4.6, P=.10) at baseline.
Further clinical information is available in Table 2.
ReMindCare Outcomes
The mean of days using the app was 352.2 (SD 191.2), which
corresponds to 11.6 months. The mean of compliance was 84.5
(16.04), and 61.1% of the ReMindCare group had a compliance
rate between 85% and 100%.
Of the 59 ReMindCare patients, 31% (18/59) requested an
urgent consultation, 20% (12/59) had a relapse while using the
app, and 8% (2/59) developed a delusion involving the app and
the research group.
After 19 months of intervention, 63% (37/59) of patients
continued using the app, while 12% (7/59) stopped using the
app because they were discharged from the FEPP and 25%
(15/59) opted to stop using ReMindCare. Reasons for
discontinuation: 33% (5/15) of patients felt suspicious about
technology (among these patients, 4 had a relapse while using
the app); 40% (6/15) perceived the app as boring and did not
perceive any benefit; and 27% (4/15) of patients left treatment
and did not continue in the program. This information is shown
in Table 3.
Table 3. Use of ReMindCare.
Min-maxRCa group (n=59)Characteristic
18-594352.2 (191.2)Days using app, mean (SD)
0-1911.6 (6.5)Months using app, mean (SD)
42-10084.5 (16.0)Engagement, mean (SD)
—b36 (61)85%-100%, n (%)
—18 (31)UCUc, n (%)
—12 (20)Relapses using app, n (%)
—2 (8)Relapses related to app, n (%)
Status of use after 19 months, n (%)
—37 (63)Patients using app
—22 (37)Patients not using app




cUCU: urgent care units.
dFEPP: first episode of psychosis program.
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With regard to the clinical outcomes, after 19 months of
ReMindCare’s integration into the clinical workflow, only 20%
(12/59) of patients from the ReMindCare group had a relapse,
while 58% (18/31) of TAU patients had one or more relapses
(χ2=13.7, P=.001). Moreover, ReMindCare patients had fewer
visits to urgent care units (χ2=7.4, P=.006) and fewer
hospitalizations than TAU patients (χ2=4.6, P=.03). Information
regarding these clinical outcomes is displayed in Table 4.
Table 4. Clinical outcomes after 19 months of the ReMindCare intervention.
χ2 (P value)TAUb, n (%)RCa group, n (%)Total, n (%)Characteristic
13.7 (.001)———cRelapses
—13 (42)47 (80)60 (67)0
—17 (55)12 (20)29 (32)1
—1 (3)0 (0)1 (1)≥2
7.4 (.006)12 (39)8 (14)20 (22)UCUd visits
4.6 (.03)6 (19)3 (5)9 (10)Hospitalizations
aRC: ReMindCare.
bTAU: treatment as usual.
cnot applicable.
dUCU: urgent care units.
Discussion
Principal Findings
The results obtained from these analyses of the first 19 months
of ReMindCare use highlight the potential benefits of this
eHealth intervention for patients with early psychosis. Patients
who used the app not only had fewer relapses than the TAU
group, but they also had fewer visits to the urgent care unit and
fewer hospitalizations.
Results related to the efficacy of the app are in line with previous
results obtained in clinical trials [14-16]. However, as far as we
know, this is the first study to identify the benefits of the use
of an app as a tool systematically integrated into daily clinical
practice in a FEPP.
With regard to the feasibility of the app, no significant
differences were found between the ReMindCare group and the
TAU group in terms of sociodemographic characteristics except
for native country. The feasibility of this intervention aligns
with the results obtained in our previous study [8], where we
found no differences in terms of sociodemographic
characteristics and interest in using eHealth interventions.
With regard to the clinical characteristics of the samples and
their impact on the effect of ReMindCare, there were some
differences between groups. We found that patients who did
not use the app were more likely to be taking injectable
medication, have a longer history of illness, and have higher
scores on the PANSS N5 and N6 negative subscales and G5 in
the general subscales. These results might suggest that the use
of ReMindCare was not indicated for chronic patients. However,
we did not find differences in other clinical scales such as the
CGI-SI, GAF, and PAS scales or even on the PANSS total scale.
More importantly, we did not find any differences between
groups in terms of baseline relapses, hospitalizations, or visits
to urgent care units.
These results are in line with the ones we obtained in our
previous study [8], where we found that interest in using eHealth
apps was equivalent between chronic and early psychosis
patients. In this regard, we suggest that differences obtained in
terms of the clinical characteristics of the patients could be more
related to the history of treatment than to clinical characteristics.
As we found, every new patient who joined the FEPP (length
of illness less than 1 year) was interested in using the app (22%
of users), while patients who had a longer history of treatment
(length of illness more than 6 years) were more likely to reject
its use (58% of TAU group). This could highlight the relevance
of introducing these new technologies at the very beginning of
treatment so early psychosis patients consider these apps to be
just another tool included in their daily clinical treatment and
not an extra service, especially since our results suggested that
use of the app had a significant impact in improving the course
of the illness.
Finally, with regard to compliance and engagement with the
app, we found that 61% of patients had compliance rates
between 85% to 100%. Rates of engagement were also high, as
63% of patients still use the app after almost 1 year. These
results of compliance and long-term engagement are contrary
to previous studies [20,21] and suggest that the use of an app
in a long-term approach is feasible and beneficial.
However, we would like to highlight that 20% of patients had
a relapse while using the app and 8% developed a delusion
involving the use of the app and the research group. These
negative results should be cautiously considered.
Technology could be a major resource to improve the quality
of treatments, but as we found in a previous study [8], it can
also play an important role as a trigger for psychotic symptoms.
In this regard, in a 3-case study in 2011 conducted by Nitzan
et al [32], they stated that the use of the internet and computers
might contribute to a gradual break with reality and development
of psychotic symptoms. They suggested that given that patients
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with psychotic diagnoses have greater difficulties in filtering
and understanding signals and symbols, they are also more
likely to misinterpret digital messages. However, no specific
studies regarding the potential harms of the use of new
technologies have been undertaken until the present.
In our study, we found that the ReMindCare app was related to
beneficial clinical effects for the vast majority of patients who
used it. However, despite the general positive effects found in
this study, there are still some barriers and negative effects that
must be taken into consideration. The main barrier found in our
study relates to the 34% of the approached patients who did not
want to use the app and who also tended to be the more chronic
patients. Moreover, the main negative effect we found related
to the 8% of patients who developed a delusion involving the
app. As a result, we would like to point out that this app is not
a panacea to prevent relapses. However, it is clear that the app
positively affected the course of the illness, as only 5% of those
who relapsed required hospitalization compared with 19% of
patients who relapsed in the TAU group.
Limitations and Strengths
There were some limitations that must be taken into
consideration. First, not every outpatient from the FEPP was
eligible for inclusion, as some patients did not have their own
smartphone with an internet connection or did not have the
ability to use the app or understand it due to language barriers.
Developing strategies to prevent digital exclusion should be a
priority to ensure that every patient could benefit from these
technologies [33]. Second, as a real-world study, this study was
not randomized. Despite the groups not differing in the vast
majority of clinical or demographic characteristics, there were
some factors such as personality that could influence our results.
The main strength of our study was the fact that ReMindCare
is the first app that has been systematically integrated into the
clinical FEPP workflow. To our knowledge, there are no
previous studies that used an app as a tool to improve the daily
treatment of patients with early psychosis. All the studies we
found were conducted in academic research settings that did
not emulate real-world environments [17,34].
Another strength is in regard to the development of the
ReMindCare app. First, it was based on two previous studies
[2,8] and co-designed with patients [27]. Second, we conducted
a pilot study and focus groups to ensure the involvement of both
patients and care providers [27] in the design and improvement
process of the app.
Finally, we would like to highlight the long-term approach of
this intervention. As stated before, ReMindCare is now
integrated into clinical practice and it was used for 19 months.
These results align with previous studies [16] that found that
people with psychosis have the abilities and interest required
to engage in long-term eHealth interventions.
Implications for the Future
As a result of these analyses, we highlighted the benefits that
the use of ReMindCare app produced on early psychosis patients
in a FEPP. Our aim is to continue improving the app in response
to the needs and suggestions provided by patients and clinicians.
As Ross et al [22] claimed in their meta-review, in order to
ensure the use of these eHealth technologies over time, there
are three challenges that should be overcome. First, the apps
must be able to adapt to the characteristics of the environment
and patients. Second, the apps should be easy to use. Third, the
apps should be integrated into clinical practice, adjusting the
characteristics of the app in order to ensure it is user-friendly
and efficient for patients and clinicians. It is our aim to address
these issues to maintain the positive results obtained in this
study.
However, we would like to point out a major issue that must
guide future eHealth interventions. As stated before, 8% of
patients developed a delusion related to the use of the app, 25%
of patients deliberately stopped using the app, and 34% of
patients approached did not want to use the app in the first place.
These results suggest that there are still significant numbers of
patients not willing to use eHealth interventions, and there are
some patients who could be adversely affected by the use of
these technologies. Studying the characteristics of these patients
should guide future research in order to ensure that the use of
digital technologies only provides benefits to the patients [8].
Finally, we would like to underline that given the exceptional
situation that the world is facing at the moment with COVID-19
and in order to address the requirements of interventions that
could improve the telematic treatment of patients and prevention
of hospital collapses [4,35], ReMindCare could be used as an
effective and efficient tool. Since quarantining in Spain began
March 13, 2020, patients have not been permitted to come in
person to their clinical appointments and have received their
clinical evaluations by phone. Since that moment, the use of
ReMindCare has been extremely useful to improve the
evaluation and adherence of early psychosis patients. However,
future analysis will be conducted in regard to this aspect.
As the conclusion of this study, we would like to point out that,
to the best of our knowledge, ReMindCare is not only the first
app to be integrated into the clinical practice, it is the first
eHealth intervention with evidence that it improves the outcomes
of early psychosis patients in a real-world care setting.
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